Rosulip M1/M2®
Rosuvastatin
Statins (Lipid Modifying Preparations)
Indication:
Hypercholesterolemia (Familial)
Mixed Dyslipidemia (Fredrickson Type IIa and IIb)
Dosage & Administration:
The usual recommended starting dose of Rosuvastatin is 10 mg once daily. Initiation of therapy with 5 mg once daily may be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy. For patients with marked hypercholesterolemia (LDL-C > 190 mg/dL) and aggressive lipid targets, a 20 mg starting dose may be considered. The 40 mg dose of Rosuvastatin should be reserved for those patients who have not achieved goal LDL-C at 20 mg. After initiation and/or upon titration of Rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
• Homozygous Hypercholesterolemia (Familial)
The recommended starting dose of Rosuvastatin is 20 mg once daily in patients with homozygous FH. The maximum recommended daily dose is 40 mg. Rosuvastatin should be used in these patients as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
• Patients with renal insufficiency
No modification of dosage is necessary for patients with mild to moderate renal insufficiency. For patients with severe renal impairment (CLcr < 30 mL/min/1.73 m2) not on hemodialysis, dosing of Rosuvastatin should be started at 5 mg once daily and not to exceed 10 mg once daily.
• Dosage in Asian Patients
Initiation of Rosuvastatin therapy with 5 mg once daily should be considered for Asian patients.
• Use with Cyclosporine, Lopinavir/Ritonavir or Atazanavir/Ritonavir
In patients taking Cyclosporine, the dose of Rosuvastatin should be limited to 5 mg once daily. In patients taking Lopinavir and Ritonavir or Atazanavir and Ritonavir the dose of Rosuvastatin should be limited to 10 mg once daily.
Preparation:
Rosulip® 10 Tablet: Each box contains 30 x 5 tablets in blister pack.
Rosulip® 20 Tablet: Each box contains 20 x 5 tablets in blister pack.